Selwyn Vickers

Selwyn Vickers

Auto-generated profile, based on publicly available information

Selwyn Vickers

University of Alabama at Birmingham, Birmingham, AL

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TJTejeshwar Jain
Tejeshwar Jain
PSPrateek Sharma
Prateek Sharma
AAAbhi C. Are
Abhi C. Are
SVSelwyn M. Vickers
Selwyn M. Vickers
VDVikas Dudeja
Vikas Dudeja
The past decade has witnessed groundbreaking advances in the field of microbiome research. An area where immense implications of the microbiome have been demonstrated is tumor biology. The microbiome affects tumor initiation and progression through direct effects on the tumor cells and indirectly through manipulation of the immune system. It can also determine response to cancer therapies and predict disease progression and survival. Modulation of the microbiome can be harnessed to potentiate the efficacy of immunotherapies and decrease their toxicity. In this review, we comprehensively dissect recent evidence regarding the interaction of the microbiome and anti-tumor immune machinery and outline the critical questions which need to be addressed as we further explore this dynamic colloquy.

1 September 2018 in Gastroenterology
Verified
Journal Article
Closed access
BGBharti Garg
Bharti Garg
BGBhuwan Giri
Bhuwan Giri
SMShrey Modi
Shrey Modi
VSVrishketan Sethi
Vrishketan Sethi
ICIris Castro
Iris Castro
VDVikas Dudeja
Vikas Dudeja

1 May 2009 in Gastroenterology
Verified
Journal Article
Open access
PDF file
VDVikas Dudeja
Vikas Dudeja
NMNameeta Mujumdar
Nameeta Mujumdar
APand Phoebe A. Phillips
and Phoebe A. Phillips
RCRohit Chugh
Rohit Chugh
DBDaniel Borja–Cacho
Daniel Borja–Cacho
ASAshok K. Saluja
Ashok K. Saluja
Background & Aims Heat shock proteins (HSPs) are highly conserved and serve a multitude of functions that mediate cell survival. HSP70, the only inducible form of the 70-kilodalton subfamily of HSPs, is overexpressed in pancreatic cancer cells and has been shown to inhibit caspase-dependent apoptosis. We aimed to elucidate the mechanism by which HSP70 inhibits apoptosis in cancer cells. Methods HSP70 expression was down-regulated in cultured pancreatic cancer cells by exposure to quercetin, triptolide, or short interfering RNAs. Intracellular Ca2+, cytosolic cathepsin B activity, caspase-3 activity, cell viability, and lysosome integrity were measured using colorimetric assays. Immunofluorescence assays were used to localize cathepsin B and Lamp2. BAPTA-AM was used to chelate intracellular Ca2+. Results Inhibition of HSP70 increased intracellular Ca2+ levels in pancreatic and colon cancer cell lines and led to loss of lysosome integrity in pancreatic cancer cells. The release of intracellular Ca2+ and lysosomal enzymes activated caspase-dependent apoptosis independently and simultaneously. Conclusions HSP70 inhibits apoptosis in cancer cells by 2 mechanisms: attenuation of cytosolic calcium and stabilization of lysosomes. HSP70-mediated cell survival might occur in other types of cancer cells.

1 March 1999 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
SVSelwyn M. Vickers
Selwyn M. Vickers
LMLee Ann MacMillan-Crow
Lee Ann MacMillan-Crow
MGMary Green
Mary Green
CEChris Ellis
Chris Ellis
JTJohn A. Thompson
John A. Thompson
HUMAN PANCREATIC adenocarcinoma remains one of the most difficult cancers to treat, as evidenced by little improvement in survival even with the addition of chemotherapy or radiation therapy. During the past 15 years, significant progress has occurred in the clinical management of pancreatic cancer due to increased early diagnosis and improved statistics on operative mortality (25% in the 1960s vs ≤5% more recently). However, the 1997 cancer statistics show that little improvement in overall patient survival has transpired from such progress. Specifically, in 1997 there were 27,600 new cases of pancreatic cancer with 28,100 deaths due to pancreatic cancer, with an overall 5-year survival of less than 5%.1,2 The simple conclusion is that current detection and therapy are not satisfactory solutions to the unremitting problem of pancreatic cancer.

11 May 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
SNSoumya J. Niranjan
Soumya J. Niranjan
JWJennifer A. Wenzel
Jennifer A. Wenzel
MMMichelle Y. Martin
Michelle Y. Martin
MFMona N. Fouad
Mona N. Fouad
SVSelwyn M. Vickers
Selwyn M. Vickers
RDRaegan W. Durant
Raegan W. Durant
PURPOSE: In general, participation rates in cancer clinical trials are very low. However, participation rates are especially low among the socially disadvantaged and racial and ethnic minority groups. These groups have been historically under-represented in cancer clinical trials. Although many patient-related barriers have been studied, institutional factors that are essential for building clinical research infrastructure around the clinical trial enterprise in academic medical centers have been underexplored. MATERIALS AND METHODS: We assessed perspectives of cancer center professional stakeholders on the institutional factors that can potentially influence racial and ethnic minority recruitment for cancer clinical trials. Ninety-one qualitative interviews were conducted at five US cancer centers among four stakeholder groups: cancer center leaders, principal investigators, referring clinicians, and research staff. Qualitative analyses examined response data focused on institutional factors related to minority recruitment for cancer clinical trials. RESULTS: Four prominent themes emerged regarding institutional barriers among clinical and research professionals. (1) There are no existing programs currently being used to recruit or retain minorities to clinical trials. (2) Institutional efforts are needed to increase trial participation and are not specific to potential minority participants. (3) Access to cancer clinical trials and navigation within an Academic Medical Center need to be simplified to better facilitate recruitment of minority patients. (4) Community outreach by cancer centers will increase clinical research awareness in the community. CONCLUSION: Our research highlights the need to address institutional barriers to improve the success of minority recruitment. To increase participation among minority populations, medical centers must address mutable institutional barriers such as setting specific minority recruitment goals for cancer clinical trials, ensuring that cancer clinical trials are accessible, especially to minority patients, and supporting sustained community outreach programs to increase clinical research awareness.

20 May 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
BGBhuwan Giri
Bhuwan Giri
VGVineet K. Gupta
Vineet K. Gupta
BYBrianna Yaffe
Brianna Yaffe
SMShrey Modi
Shrey Modi
PRPooja Roy
Pooja Roy
ASAshok Saluja
Ashok Saluja
There is an urgent need for novel and effective treatment options for acute myeloid leukemia (AML). Triptolide, a diterpenoid tri-epoxide compound isolated from the herb Tripterygium wilfordii and its water-soluble pro-drug-Minnelide have shown promising anti-cancer activity. A recent clinical trial for patients with solid tumors confirmed the safety and efficacy at biologically equivalent doses of 0.2 mg/kg/day and lower. Cell viability of multiple AML cell lines as well as patient apheresis samples were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) based assay. Apoptosis was evaluated by estimating the amount of cleaved caspase. AML cell line (THP1-Luc) was implanted in immunocompromised mice and treated with indicated doses of Minnelide. Leukemic burden before and after treatment was evaluated by imaging in an In Vivo Imaging System (IVIS). In the current study, we show that Minnelide, at doses below maximum tolerated dose (MTD) demonstrates leukemic clearance of both primary AML blasts and luciferase expressing THP-1 cells in mice. In vitro, multiple primary AML apheresis samples and AML cell lines (THP-1, KG1, Kasumi-1, HL-60) were sensitive to triptolide mediated cell death and apoptosis in low doses. Treatment with triptolide led to a significant decrease in the colony forming ability of AML cell lines as well as in the expression of stem cell markers. Additionally, it resulted in the cell cycle arrest in the G1/S phase with significant downregulation of c-Myc, a major transcriptional regulator mediating cancer cell growth and stemness. Our results suggest that Minnelide, with confirmed safety and activity in the clinic, exerts a potent anti-leukemic effect in multiple models of AML at doses easily achievable in patients.